Role of Linzess in Managing Chronic Constipation

Introduction to Linzess

The American Gastroenterological Association strongly recommends Linzess (linaclotide) as a second-line treatment for adults with chronic idiopathic constipation (CIC) who do not respond to over-the-counter laxatives, with high-quality evidence supporting its efficacy in improving bowel movements, stool consistency, and quality of life 1, 2

Linaclotide is a guanylate cyclase-C agonist that increases cyclic guanosine monophosphate concentrations, resulting in luminal chloride and bicarbonate secretion, thereby increasing intestinal fluid and accelerating gastrointestinal transit 1, 2
Significantly increases complete spontaneous bowel movements (CSBMs) per week by 1.37 compared to placebo 2
Increases spontaneous bowel movements (SBMs) per week by 1.97 compared to placebo 2
Improves stool consistency (MD 1.25 on Bristol Stool Scale) 2
Triples responder rates compared to placebo (RR 3.14) 2
Increases rates of global relief (RR 1.96) 2
May improve patient quality of life scores, though data could not be pooled in studies 2

For CIC: 72μg or 145μg once daily 2
Should be taken on an empty stomach, at least 30 minutes before the first meal of the day 2
Duration of treatment in clinical trials was 12 weeks, but the drug label does not provide a limit on treatment duration 2

Most common adverse effect is diarrhea, which may lead to treatment discontinuation in some patients (approximately 4.7% in studies) 2, 3
Patients treated with linaclotide are about 3 times more likely to experience diarrhea leading to treatment discontinuation compared with placebo 2
Contraindicated in patients with known or suspected mechanical gastrointestinal obstruction 2
The most common reasons for discontinuation over the first year of treatment were loss of efficacy and insurance coverage barriers rather than adverse events 3

Efficacy appears similar in patients over 65 years of age compared to the general population, though sample sizes in studies were limited 2, 3

Start with over-the-counter laxatives as first-line therapy 1, 2
For patients who do not respond adequately to OTC agents, add or switch to linaclotide (72μg or 145μg daily) 2
Linaclotide can be used as a replacement for or as an adjunct to OTC agents 2
Consider linaclotide particularly for patients with concurrent abdominal symptoms (bloating, discomfort, pain) 2
If diarrhea occurs and is problematic, consider dose reduction 3

The American Gastroenterological Association recommends linaclotide as a second-line agent for IBS-C and CIC after failure of first-line therapies, with a strength of evidence supporting its efficacy as a secretagogue 4, 5

For IBS-C in adults, a dose of 290 mcg orally once daily is consistently used across multiple high-quality trials, demonstrating significant improvements in the FDA composite endpoint, with a responder rate of 33.6-33.7% vs. 13.9-21.0% for placebo 6, 7, 8, 9
For CIC in adults, the standard starting dose is 145 mcg once daily, with an alternative dose of 72 mcg once daily based on individual presentation or tolerability concerns, achieving responder rates of 12.4% vs. 4.7% placebo 4, 5

The British Society of Gastroenterology recommends linaclotide as a second-line agent for IBS-C and CIC, considering it the most efficacious secretagogue available, with a strength of evidence supporting its use after inadequate response to dietary modifications and first-line agents 4, 5
The American Gastroenterological Association and British Society of Gastroenterology guidelines support the use of linaclotide for IBS-C and CIC, with recommendations for dosing and administration, including taking on an empty stomach at least 30 minutes before the first meal of the day 6, 7, 4, 5

Patients on concurrent medications that affect sodium balance, such as diuretics, may be at higher risk of hyponatremia when taking Linzess 10